Result of General Meeting

RNS Number : 9821W
NetScientific PLC
24 August 2020
 

NetScientific plc

("NetScientific" or the "Company")

Result of General Meeting

NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, is pleased to announce at its General Meeting held earlier today all resolutions were duly passed.

Accordingly, the Company has today authorised:

1.  a capital reorganisation which has the effect of consolidating ten Existing Ordinary Shares into one New Ordinary Share;

2.  the issue of 3,538,455 New Ordinary Shares at an Issue Price of 65p pence raising gross proceeds of approximately £2.3 million through a placing (the "Placing") with institutional and other investors;

3.  the issue of 3,521,480 New Ordinary Shares to Futura Messis Group Ltd pursuant to the acquisition of EMV Capital Ltd (the "Acquisition"); and

4.  The adoption by the Company of the new Articles of Association.

The full details of the Acquisition, Placing and Capital Reorganisation are set out in the announcement dated 5 August 2020.

John Clarkson, Chairman, said "the Board of NetScientific want to express their gratitude to shareholders for their overwhelming vote of support, enabling the transformation of the business, which is now positioned for future success".

 

Admission to Trading on AIM

Further to the announcement on 5 August 2020, application for admission to trading of the New Ordinary Shares has been made and it is anticipated that admission will take place at 8.00 a.m. on 25 August 2020 ("Admission").

In accordance with the provisions of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, the Company confirms that, following the Acquisition, Placing and Capital Reorganisation, its issued share capital will comprise 14,916,122 New Ordinary Shares upon Admission. All of these New Ordinary Shares have equal voting rights and none of the New Ordinary Shares are held in treasury. The total number of voting rights in the Company will therefore be 14,916,122 upon Admission.

Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the announcement dated 5 August 2020.



 

The full details of the votes cast are as follows.



Votes Cast


% of Votes Cast

Resolution No.

Resolution Text

For

Against


For

Against

Special Resolution 1

To adopt the new Articles of Association of the Company

23,518,025

421,879


98.2%

1.8%

Ordinary Resolution 2

To approve the proposed sub-division

23,508,223

431,681


98.2%

1.8%

Ordinary Resolution 3

To approve the proposed consolidation

23,511,134

428,770


98.2%

1.8%

Ordinary Resolution 4

To approve the waiver granted by the Panel on Takeovers and Mergers of any requirement under Rule 9 on the Concert Party to make a general offer to shareholders

23,513,842

425,777


98.2%

1.8%

Ordinary Resolution 5

To authorise the Directors to allot shares in the Company in respect of the Consideration and Placing Shares

23,446,323

493,581


97.9%

2.1%

Ordinary Resolution 6

To authorise the Directors to allot shares in the Company generally

23,446,038

493,581


97.9%

2.1%

Special Resolution 7

To disapply statutory pre-emption rights in respect of the Placing Shares

23,446,038

493,581


97.9%

2.1%

Special Resolution 8

To disapply statutory pre-emption rights generally

23,446,038

493,581


97.9%

2.1%

 

# # #

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Following the publication of this announcement, this inside information is now considered to be in the public domain.

For more information, please contact:

NetScientific 

Ilian Iliev, CEO  Tel: +44 (0)20 3514 1800

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Jessica Cave / Darshan Patel  Tel: +44 (0)20 7220 1666

MO PR ADVISORY (Press Contact)

Mo Noonan  Tel: +44 (0)78 7644 4977

About NetScientific

NetScientific PLC is a transatlantic healthcare IP commercialisation Group focused on technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people.

For more information, please visit the website at      www.NetScientific.net

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMSEIFSLESSEEA
UK 100

Latest directors dealings